



## **Nkarta to Participate at Upcoming Investor Conferences**

February 9, 2023

SOUTH SAN FRANCISCO, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at three upcoming investor conferences:

**SVB Securities Global Biopharma Conference**

February 14, 2023

3:40 p.m. ET – fireside chat

**H.C. Wainwright Cell Therapy Virtual Conference**

February 28, 2023

Time tbd – fireside chat

**Cowen 43<sup>rd</sup> Annual Health Care Conference**

March 8, 2023

2:10 p.m. ET – industry panel discussion

A simultaneous webcast of each event will be available on the Investors section of Nkarta's website, [www.nkartatx.com](http://www.nkartatx.com), and a replay will be archived on the website for approximately 90 days.

**About Nkarta**

Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for cancer patients. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep anti-tumor activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company's website at [www.nkartatx.com](http://www.nkartatx.com).

**Nkarta Media/Investor Contact:**

Greg Mann

Nkarta, Inc.

[gmann@nkartatx.com](mailto:gmann@nkartatx.com)